SCHEMBL8010389

SCHEMBL8010389

CC(C)=CCC/C(C)=C/CC/C(C)=C/Cc1cc(C(=O)O)ccc1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.53
PPARG P37231 2/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
DNMT1 P26358 1/20 0.48
SIRT5 Q9NXA8 1/20 0.48
MRGPRX4 Q96LA9 2/20 0.47
ICMT O60725 1/20 0.47
CNR2 P34972 1/20 0.47
TRPV1 Q8NER1 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER3 P43115 1/20 0.43
PTGER2 P43116 1/20 0.43
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8020241 0.99 BACE1 (0.51) BACE1PPARGPPARDPPARADNMT1
SCHEMBL8021150 0.91 ICMT (0.45) BACE1PPARGPPARDPPARADNMT1
SCHEMBL27639554 0.90 PPARG (0.45) BACE1PPARGPPARDPPARADNMT1
SCHEMBL12702799 0.90 TRPV1 (0.46) BACE1PPARGPPARDPPARADNMT1
SCHEMBL8011289 0.85 PPARG (0.46) PPARGPPARDPPARADNMT1SIRT5
SCHEMBL8011278 0.85 BACE1 (0.55) BACE1PPARGPPARDPPARADNMT1
SCHEMBL8027765 0.84 BACE1 (0.54) BACE1CNR2TRPV1
SCHEMBL12702765 0.84 PPARG (0.47) PPARGPPARDPPARADNMT1SIRT5
SCHEMBL8009534 0.84 BACE1 (0.53) BACE1PPARGPPARDPPARADNMT1
SCHEMBL8019435 0.83 BACE1 (0.58) BACE1PPARGPPARDPPARADNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092591-A1 PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA S.A. (ES) 2011-04-21 US disclosed
US-20110092591-A1 PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA S.A. (ES) 2011-04-21 US disclosed
WO-2009098287-A1 PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA S.A. (ES) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092591-A1 PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS PSEN1, PARK7, APP BACE1 8/4885PPARG 699/4885PPARD 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.